Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 5/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | EP300 | Q09472 | 1/20 | 0.40 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31456729 | 0.78 | CYP2A6 (0.53) | CYP2A6CYP3A4CYP2E1ALDH1A1HTT | |
| SCHEMBL1127502 | 0.76 | ATM (0.48) | CYP3A4ALDH1A1ALOX12GAAMAPT | |
| SCHEMBL3607993 | 0.76 | CYP2A6 (0.55) | CYP2A6CYP3A4CYP2E1ALDH1A1HTT | |
| SCHEMBL28195188 | 0.76 | CYP2A6 (0.50) | CYP2A6CYP3A4CYP2E1ALDH1A1HTT | |
| SCHEMBL18878398 | 0.76 | CYP2A6 (0.50) | CYP2A6CYP3A4CYP2E1ALDH1A1HTT | |
| SCHEMBL31310093 | 0.76 | CYP2A6 (0.46) | CYP2A6CYP3A4CYP2E1ALDH1A1HTT | |
| SCHEMBL27496380 | 0.76 | CYP2A6 (0.50) | CYP2A6CYP3A4CYP2E1ALDH1A1HTT | |
| SCHEMBL17521752 | 0.76 | CYP2A6 (0.50) | CYP2A6CYP3A4CYP2E1ALDH1A1HTT | |
| SCHEMBL22339813 | 0.76 | CYP2A6 (0.50) | CYP2A6CYP3A4CYP2E1ALDH1A1HTT | |
| SCHEMBL4884791 | 0.75 | CYP2A6 (0.53) | CYP2A6CYP3A4CYP2E1ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3885343-A1 | INDOLE COMPOUNDS AS EZH2 INHIBITORS AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-20170360801-A1 | BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170145023-A1 | DIAZEPANE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170145013-A1 | DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-8759539-B2 | Substituted bicyclic amines for the treatment of diabetes | MERCK SHARP & DOHME CORP. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8759539-B2 | Substituted bicyclic amines for the treatment of diabetes | MERCK SHARP & DOHME CORP. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20110207737-A1 | SUBSTITUTED BICYCLIC AMINES FOR THE TREATMENT OF DIABETES | MERCK SHARP & DOHME CORP | 2011-08-25 | — | — | US | disclosed |
| US-20110207737-A1 | SUBSTITUTED BICYCLIC AMINES FOR THE TREATMENT OF DIABETES | MERCK SHARP & DOHME CORP | 2011-08-25 | — | — | US | disclosed |
| WO-2010056717-A1 | SUBSTITUTED BICYCLIC AMINES FOR THE TREATMENT OF DIABETES | MERCK SHARP & DOHME CORP. (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2008086158-A1 | BENZODIHYDROQUINAZOLINE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | BRDT, BRD4, BRD1 | CYP2A6 4574/4885CYP3A4 4684/4885CYP2E1 4024/4885 |
| US-20110207737-A1 | SUBSTITUTED BICYCLIC AMINES FOR THE TREATMENT OF DIABETES | SSTR5, TAAR5, MC5R | CYP2A6 3173/4885CYP3A4 2954/4885CYP2E1 3124/4885 |
| US-20170360801-A1 | BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY | BRDT, BRD4, BRD1 | CYP2A6 4574/4885CYP3A4 4684/4885CYP2E1 4024/4885 |
| US-20170145013-A1 | DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF | BRDT, BRD4, BRD3 | CYP2A6 2956/4885CYP3A4 4229/4885CYP2E1 1791/4885 |
| US-20170145023-A1 | DIAZEPANE DERIVATIVES AND USES THEREOF | BRDT, BRD4, BAZ2A | CYP2A6 2832/4885CYP3A4 3930/4885CYP2E1 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.